KVACW_OUT_1 [2025-04-24 04:46:02 -0400] 2480 Bytes | 629 tokens | Cum: 629 tkns (7.86% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Keen Vision Acquisition (KVACW) which is at $0.0626 up from $0.0500. So, I pulled together a bunch of data for you to look over real fast. It's still early, 4:46 AM on Thu Apr 24, 2025. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Keen Vision Acquisition (KVACW)
IPO: 2023-09-15 (1 Year Ago)
Industry: BLANK CHECKS
Exchange: XNAS
Description: Keen Vision Acquisition Corp is a blank check company.

Here’s a list of headlines for Keen Vision Acquisition:

No news available.

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-17T23:00:00Z - $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NHHS, KVAC, AMPS, AVTE
B2 - 2025-03-11T13:09:44Z - Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
B3 - 2025-02-07T13:00:00Z - Medera, Inc. to Participate in Two Upcoming Investor Conferences

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Keen Vision Acquisition (KVACW).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

KVACW_OUT_3 [2025-04-24 04:46:03 -0400] 831 Bytes | 234 tokens | Cum: 865 tkns (10.81% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NHHS, KVAC, AMPS, AVTE**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/17/3044157/0/en/HAREHOLDER-ALERT-The-M-A-Class-Action-Firm-Continues-To-Investigate-The-Merger-NHHS-KVAC-AMPS-AVTE.htmlThe M&A Class Action Firm is investigating the proposed mergers of NorthStar Healthcare Income, Keen Vision Acquisition Corp., Altus Power, and Aerovate Therapeutics, providing information and options for shareholders.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_5 [2025-04-24 04:46:07 -0400] 643 Bytes | 162 tokens | Cum: 1029 tkns (12.86% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T12:00:00Z - Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Prese...
A2 - 2025-04-01T12:21:23Z - Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Prese...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

KVACW_OUT_7 [2025-04-24 04:46:08 -0400] 1182 Bytes | 311 tokens | Cum: 1342 tkns (16.78% of 8k)
==========================================================================

Showing A1 (chunk 1 of 22): A1:
**Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit - Keen Vision Acquisition (NASDAQ:KVAC)**Date: 2025-04-01Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/04/g44582849/medera-presented-updated-results-from-first-in-human-gene-therapy-trial-for-heart-failure-with-preBOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_9 [2025-04-24 04:46:09 -0400] 1182 Bytes | 286 tokens | Cum: 1630 tkns (20.38% of 8k)
==========================================================================

Showing A1 (chunk 2 of 22): the 2025 HFpEF Summit held March 19-21, 2025, in Beverly Hills, CA.

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year. Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics. SRD-002 is a gene therapy utilizing an adeno-associated type 1 virus vector carrying the cardiac isoform of the sarcoplasmic reticulum calcium ATPase pump (SERCA2a) that directly targets the molecular pathways underlying the core pathology of HFpEF by enhancing myocardial relaxation and reducing stiffness.

The presentation titled, "Targeting Diastolic Dysfunction in HFpEF- SERCA2a Gene Therapy," was delivered by Marat Fudim, MD, MHS, Advanced Heart Failure Specialist and Associate Professor at Duke University Medical Center and site principal investigat

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_11 [2025-04-24 04:46:10 -0400] 1188 Bytes | 300 tokens | Cum: 1932 tkns (24.15% of 8k)
==========================================================================

Showing A1 (chunk 3 of 22): or, on Friday, March 21st. The presentation highlighted data from the trial, which, as of the data cutoff date of February 25, 2025, has treated five patients in Cohort A with a low dose of 3×10¹³ viral genomes (vg) per patient and one patient has been dosed in Cohort B at a dose of 4.5×10¹³ vg per patient. With follow-up ranging from 2 to 15 months, no gene therapy-related serious adverse events have been reported. Four out of the five patients in the low-dose group have shown improvements in New York Heart Association (NYHA) heart failure classification at 6 months, with clinically meaningful improvements in 6-minute walk test (6MWT), decreases/stabilization in NT-Pro-BNP, and high-sensitivity troponin observed in some patients. The enrollment of patients at the higher dose of 4.5x1013 vg per patient is ongoing.

"New treatment approaches, like Medera's gene therapy product, targeting

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_13 [2025-04-24 04:46:11 -0400] 1182 Bytes | 247 tokens | Cum: 2181 tkns (27.26% of 8k)
==========================================================================

Showing A1 (chunk 4 of 22): critical pathways in the heart, are crucial for patients and caregivers faced with this difficult-to-treat disease," stated Marat Fudim, MD, MHS, Advanced Heart Failure Specialist and Associate Professor at Duke University Medical Center and site principal investigator. "The encouraging early results presented at this summit reflect important progress in this critical research."

"We are excited to share our encouraging results from the MUSIC-HFpEF trial at this prestigious summit," said Ronald Li, Ph.D., CEO and co-founder of Medera. "This groundbreaking trial represents the first-in-human gene therapy approach for patients with HFpEF and features unique hemodynamic characterization of patients within the study using precise measurements of pulmonary capillary wedge pressure (PCWP) at rest and during exercise. Our clinical findings suggest this approach may offer an alternative treatmen

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_15 [2025-04-24 04:46:12 -0400] 1182 Bytes | 274 tokens | Cum: 2457 tkns (30.71% of 8k)
==========================================================================

Showing A1 (chunk 5 of 22): t strategy to HFpEF patients, where a significant unmet need remains."

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest insights and innovations for scientists, clinicians, researchers, and other healthcare professionals interested in all aspects of HFpEF.

For additional information about the MUSIC-HFpEF trial, visit ClinicalTrials.gov using the study identifier NCT06061549.

On September 5, 2024, Medera and Keen Vision Acquisition Corporation ("KVAC") KVAC KVACW)), announced they had entered into a definitive merger agreement.

About Heart Failure with Preserved Ejection Fraction (HFpEF)

Heart failure (HF) is a global pandemic with an estimated 64.3 million cases worldwide and a rising prevalence trend. Accounting for 50% or more of the

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_17 [2025-04-24 04:46:12 -0400] 1186 Bytes | 262 tokens | Cum: 2721 tkns (34.01% of 8k)
==========================================================================

Showing A1 (chunk 6 of 22): overall HF population, HFpEF is an age-related condition that has become increasingly prevalent in recent years. This surge is partly due to better awareness and identification of the condition and partly due to lifestyle changes affecting cardiac myocytes. Individuals affected by HFpEF experience similar morbidity and mortality to patients with HF with reduced ejection fraction (HFrEF). Despite the growing epidemic of this emerging syndrome, HFpEF-focused interventional trials have had little success, except for the use of sacubitril-valsartan (Entresto™) and the sodium glucose transporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance™) for reducing cardiovascular mortality and heart failure hospitalization. However, these agents are not disease-modifying, highlighting the critical need for therapeutic interventions targeting the physiological mechanisms involved in HFpEF.

About Medera

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_19 [2025-04-24 04:46:13 -0400] 1182 Bytes | 247 tokens | Cum: 2970 tkns (37.12% of 8k)
==========================================================================

Showing A1 (chunk 7 of 22):

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via its two preclinical and clinical business units, Novoheart and Sardocor, respectively.

Novoheart capitalizes on the world's first and award-winning "mini-Heart" Technology for revolutionary disease modelling and drug discovery, uniquely enabling the modelling of human-specific diseases and discovery of therapeutic candidates free from species-specific differences in accordance to the FDA Modernization Act 2.0. Novoheart's versatile technology platform provides a range of state-of-the-art automation hardware and software as well as screening services, for human-specific disease modelling, therapeutic target discovery and validation, drug toxicity and efficacy screening, and dosage optimiz

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_21 [2025-04-24 04:46:14 -0400] 1182 Bytes | 253 tokens | Cum: 3225 tkns (40.31% of 8k)
==========================================================================

Showing A1 (chunk 8 of 22): ation carried out in the context of healthy and/or diseased human heart chambers and tissues. Global pharmaceutical and academic leaders are using Novoheart's technology platform for their drug discovery and development purposes. The Novoheart platform has facilitated and accelerated the development of Sardocor's lead therapeutic candidates that are currently in clinical trials.

Sardocor is dedicated to the clinical development of novel next-generation therapies for Medera. Leveraging Novoheart's human-based drug discovery and validation platforms, Sardocor aims to expedite drug development and regulatory timelines for its gene and cell therapy pipeline. Sardocor has received Investigational New Drug (IND) clearances from the FDA for three ongoing AAV-based cardiac gene therapy clinical trials targeting Heart Failure with Reduced Ejection Fraction (HFrEF), Heart Failure with Preserved E

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_23 [2025-04-24 04:46:15 -0400] 1182 Bytes | 261 tokens | Cum: 3488 tkns (43.60% of 8k)
==========================================================================

Showing A1 (chunk 9 of 22): jection Fraction (HFpEF) with the Fast Track Designation, and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM) with the Orphan Drug Designation. Additionally, Sardocor's pipeline includes four preclinical gene therapy and three preclinical small molecule candidates targeting various cardiac, pulmonary, and vascular diseases.

For more information, please visit www.medera.bio.

About Keen Vision Acquisition Corporation

Keen Vision Acquisition Corp ("KVAC"), listed on Nasdaq, is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. KVAC is focused on biotechnology, consumer goods or agriculture opportunities, which are also evaluated on their sustainability, environmental, social, and corporate governance ("ESG") imper

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_25 [2025-04-24 04:46:15 -0400] 1183 Bytes | 267 tokens | Cum: 3757 tkns (46.96% of 8k)
==========================================================================

Showing A1 (chunk 10 of 22): atives.

For more information, please visit www.kv-ac.com.

Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release are forward-looking statements. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are also forward-looking statements. In some cases, you can identify forward-looking statements by words such as "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "strategy," "future," "opportunity," "may," "target," "should," "will," "would," "will be," "will continue," "will likely result,"

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KVACW_OUT_27 [2025-04-24 04:46:16 -0400] 238 Bytes | 59 tokens | Cum: 3818 tkns (47.73% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KVACW_OUT_29 [2025-04-24 04:46:16 -0400] 251 Bytes | 78 tokens | Cum: 3899 tkns (48.74% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

KVACW_OUT_31 [2025-04-24 04:46:24 -0400] 4049 Bytes | 1078 tokens | Cum: 4980 tkns (62.25% of 8k)
==========================================================================

This is our set of metrics for Keen Vision Acquisition.
Please analyze the numbers.

No Finviz metrics available.

The next section covers any insider trading by Keen Vision Acquisition officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': 7409180.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.0626
Average Volume: 62281.65
30-Day High: 0.0626
30-Day Low: 0.0302

[Detailed Financials: TTM 2024]
- Total Assets: $70,436,851.00
- Total Liabilities: $4,262,898.00
- Total Equity: $-4,199,112.00
- Current Assets: $63,786.00
- Current Liabilities: $1,272,898.00

[Income Statement: TTM 2024]
- Revenue: N/A
- Net Income: $7,409,180.00
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-577,205.00

[Detailed Financials: FY 2024]
- Total Assets: $70,436,851.00
- Total Liabilities: $4,262,898.00
- Total Equity: $-4,199,112.00
- Current Assets: $63,786.00
- Current Liabilities: $1,272,898.00

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: $7,409,180.00
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-577,205.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Keen Vision Acquisition (KVACW).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Keen Vision Acquisition.

2) MARKET_SCORE[]
This conversation was initiated because KVACW is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for KVACW.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, KVACW could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect KVACW to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Keen Vision Acquisition.

11) ETHICAL_RATING[]
Rate Keen Vision Acquisition’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Keen Vision Acquisition.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

KVACW_IN_33 [2025-04-24 04:46:24 -0400] 126 Bytes | 29 tokens | Cum: 5241 tkns (65.51% of 8k)
==========================================================================

====================================
[2025-04-24 04:46:24] # Analysis Completed
Elapsed Time: 22.68 seconds